On July 4, the Alberta Court of Appeal held that a corporation cannot be represented in the superior courts by a non-lawyer. Madam Justice Rowbotham’s decision in Park Avenue Flooring Inc v EllisDon Construction Services Inc concerned an appeal by Park Avenue that included an application for an order permitting Deborah Miller, a director and officer of Park Avenue, to represent Park Avenue for the appeal.
July 13, 2016
After dismissing interim and interlocutory injunction motions, the Federal Court awarded costs to the successful defendant at a quantum higher than stipulated in Column III of Tariff B of the Federal Courts Rules.
On June 24th, the Patented Medicine Prices Review Board (PMPRB) published “PMPRB Guidelines Modernization Discussion Paper” (Discussion Paper).
July 12, 2016
The proliferation of medical marijuana dispensaries in cities such as Vancouver and Toronto has prompted city councillors to crack down—albeit in different ways—on these illegal businesses.
Welcome to our July edition of Legalseas exploring topical issues and law reforms in the shipping sector.
On March 30, 2016, the Quebec Superior Court awarded more than $1.2 million to a man who is now paralyzed after falling in the parking lot of his apartment. In making this award, the court had to consider the vulnerability of the victim due to a serious pre-existing condition which may have contributed to his injuries, in accordance with a principle known as the “thin skull rule.”
July 11, 2016
The College of Pharmacists of British Columbia (CPBC) is the regulatory body responsible for licensing and registering
July 08, 2016
The Supreme Court of Canada recently denied the O’Chiese First Nation leave to appeal the Alberta Court of Appeal’s (ABCA) decision in O’Chiese First Nation v Alberta Energy Regulator, 2015 ABCA 348, which refused to overturn a standing decision made by the Alberta Energy Regulator (AER).
July 05, 2016
In January 2015, the Patented Medicine Prices Review Board (PMPRB or Board) commenced a proceeding against Alexion Pharmaceuticals Inc. alleging it had sold its drug SOLIRIS® (eculizumab) at an excessive price.
July 04, 2016
Welcome to the latest edition of Legalflyer.
July 01, 2016
Try searching our global site instead